{
  "id": 3523970,
  "title": "FDA support advances biomarker for earlier, more precise Parkinson's clinical trials",
  "url": "https://urgent.news/2026/08/26/fda-support-advances-biomarker-for-earlier-more-precise-parkinsons",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-26T13:40:11.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-fda-advances-biomarker-earlier-precise.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "The Critical Path Institute (C-Path) has published \"Regulatory endorsement for the application of alpha-synuclein seed amplification assay (αSyn-SAA) as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies\" in the Journal of Parkinson's Disease, marking a significant milestone for its Critical Path for Parkinson's consortium. The findings detail scientific,…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}